239 related articles for article (PubMed ID: 21366911)
1. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.
Connick P; Kolappan M; Patani R; Scott MA; Crawley C; He XL; Richardson K; Barber K; Webber DJ; Wheeler-Kingshott CA; Tozer DJ; Samson RS; Thomas DL; Du MQ; Luan SL; Michell AW; Altmann DR; Thompson AJ; Miller DH; Compston A; Chandran S
Trials; 2011 Mar; 12():62. PubMed ID: 21366911
[TBL] [Abstract][Full Text] [Related]
2. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
[TBL] [Abstract][Full Text] [Related]
3. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
Trials; 2019 May; 20(1):263. PubMed ID: 31072380
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.
Rice CM; Marks DI; Ben-Shlomo Y; Evangelou N; Morgan PS; Metcalfe C; Walsh P; Kane NM; Guttridge MG; Miflin G; Blackmore S; Sarkar P; Redondo J; Owen D; Cottrell DA; Wilkins A; Scolding NJ
Trials; 2015 Oct; 16():463. PubMed ID: 26467901
[TBL] [Abstract][Full Text] [Related]
5. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
[TBL] [Abstract][Full Text] [Related]
7. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial.
Kim SJ; Moon GJ; Chang WH; Kim YH; Bang OY;
Trials; 2013 Oct; 14():317. PubMed ID: 24083670
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
9. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
[TBL] [Abstract][Full Text] [Related]
11. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
Harris VK; Yan QJ; Vyshkina T; Sahabi S; Liu X; Sadiq SA
J Neurol Sci; 2012 Feb; 313(1-2):167-77. PubMed ID: 21962795
[TBL] [Abstract][Full Text] [Related]
14. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
15. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.
Bonab MM; Sahraian MA; Aghsaie A; Karvigh SA; Hosseinian SM; Nikbin B; Lotfi J; Khorramnia S; Motamed MR; Togha M; Harirchian MH; Moghadam NB; Alikhani K; Yadegari S; Jafarian S; Gheini MR
Curr Stem Cell Res Ther; 2012 Nov; 7(6):407-14. PubMed ID: 23061813
[TBL] [Abstract][Full Text] [Related]
16. Autologous Stem Cells in Achilles Tendinopathy (ASCAT): protocol for a phase IIA, single-centre, proof-of-concept study.
Goldberg AJ; Zaidi R; Brooking D; Kim L; Korda M; Masci L; Green R; O'Donnell P; Smith R
BMJ Open; 2018 May; 8(5):e021600. PubMed ID: 29764889
[TBL] [Abstract][Full Text] [Related]
17. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK; Vyshkina T; Sadiq SA
Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
[TBL] [Abstract][Full Text] [Related]
18. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy.
Centeno C; Markle J; Dodson E; Stemper I; Williams CJ; Hyzy M; Ichim T; Freeman M
J Transl Med; 2017 Sep; 15(1):197. PubMed ID: 28938891
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.
Zamboni P; Bertolotto A; Boldrini P; Cenni P; D'Alessandro R; D'Amico R; Del Sette M; Galeotti R; Galimberti S; Liberati A; Massacesi L; Papini D; Salvi F; Simi S; Stella A; Tesio L; Valsecchi MG; Filippini G;
Trials; 2012 Oct; 13():183. PubMed ID: 23034121
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
